Blog
RSS FeedPosted by Michael Wonder on 21 Aug 2023
ICER publishes final evidence report on gene therapies for sickle cell disease
21 August 2023 - Current evidence suggests that lovo-cel and exa-cel would achieve common thresholds for cost-effectiveness if priced between $1.35 ...
Posted by Michael Wonder on 25 May 2023
ICER publishes final evidence report on treatments for non-alcoholic steatohepatitis
25 May 2023 - Independent appraisal committee narrowly voted that currently available evidence for resmetirom is adequate to demonstrate a net ...
Posted by Michael Wonder on 02 Nov 2022
ICER publishes evidence report on gene therapies for haemophilia A and B
2 November 2022 - Duration of benefit with gene therapies and risks for rare side effects remain major uncertainties. ...
Posted by Michael Wonder on 20 Oct 2022
ICER publishes final evidence report and policy recommendations on treatments for obesity management
20 October 2022 - Independent appraisal committee voted that evidence is adequate to demonstrate that semaglutide provides a net health benefit ...
Posted by Michael Wonder on 13 Sep 2022
ICER publishes final evidence report and policy recommendations on treatments for amyotrophic lateral sclerosis
13 September 2022 - Majority of independent appraisal committee voted that evidence is adequate to demonstrate that both AMX0035 and oral ...
Posted by Michael Wonder on 19 Jul 2022
ICER publishes final evidence report and policy recommendations on beti-cel gene therapy for beta thalassaemia
19 July 2022 - Independent appraisal committee unanimously determined that evidence is adequate to demonstrate that beti-cel provides a net ...
Posted by Michael Wonder on 10 May 2022
ICER publishes final evidence report and policy recommendations on outpatient treatments for COVID-19
10 May 2022 - Independent appraisal committee votes 11-2 that the evidence is not adequate to demonstrate a net health benefit ...
Posted by Michael Wonder on 15 Feb 2022
ICER publishes final evidence report and policy recommendations on tirzepatide for type 2 diabetes
15 February 2022 - Independent appraisal committee found that evidence is adequate to demonstrate a net health benefit of tirzepatide added ...
Posted by Michael Wonder on 03 Feb 2022
ICER releases draft evidence report on treatments for COVID-19
3 February 2022 - Public comment period now open until 3 March 2022; requests to make oral comment during public ...
Posted by Michael Wonder on 16 Dec 2021
ICER publishes final evidence report and policy recommendations on tezepelumab for severe asthma
16 December 2021 - Independent appraisal committee found that evidence is adequate to demonstrate a net health benefit of tezepelumab ...
Posted by Michael Wonder on 07 Oct 2021
ICER publishes evidence report on mavacamten for hypertrophic cardiomyopathy
7 October 2021 - Evidence is rated as promising but inconclusive to determine whether mavacamten provides a net health benefit for ...
Posted by Michael Wonder on 17 Aug 2021
ICER publishes final evidence report and policy recommendations on therapies for atopic dermatitis
17 August 2021 - Given uncertainty about safety data on oral JAK inhibitors for other indications, a narrow majority of the ...
Posted by Michael Wonder on 05 Aug 2021
ICER publishes final evidence report and policy recommendations on aducanumab for Alzheimer’s disease
5 August 2021 - Independent appraisal committee unanimously determined the evidence is not adequate to demonstrate that aducanumab provides a net ...
Posted by Michael Wonder on 30 Jun 2021
In revised evidence report, ICER confirms judgment that evidence is insufficient to demonstrate net health benefit of aducanumab for patients with Alzheimer’s disease
30 June 2021 - Accepting the uncertainty associated with the positive estimate obtained from pooled data from both pivotal trials, ...
Posted by Michael Wonder on 11 May 2021
ICER publishes final evidence report and policy recommendations on therapies for multiple myeloma
11 May 2021 - Independent appraisal committee unanimously determined the evidence is adequate to demonstrate that CAR-T treatments ide-cel and cilta-cel ...